X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

Company Overview

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency that can cause chronic neutropenia, lymphopenia and recurrent infections. XOLREMDI is designed to increase the number of circulating neutrophils and lymphocytes, potentially helping reduce infection-related complications.

Founded in 2014 and headquartered in Boston, Massachusetts, X4 Pharmaceuticals has historically focused on rare immunological and hematological disorders with significant unmet medical needs. In addition to its commercial efforts for XOLREMDI in the United States, the company has evaluated mavorixafor in other forms of chronic neutropenia and related conditions. X4 Pharmaceuticals trades on the Nasdaq under the symbol XFOR.

Key Stats

• Today's Range: $2.47 to $2.66
• 50-Day Range: $2.45 to $4.64
• 52-Week Range: $2.43 to $4.83
• Volume: 549,832 shs
• Average Volume: 955,810 shs
• Market Capitalization: $261.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.25
• Consensus Rating: Moderate Buy

X4 Pharmaceuticals Stock Analysis - MarketRank™

X4 Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 643rd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

X4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

X4 Pharmaceuticals has a consensus price target of $11.25, representing about 326.1% upside from its current price of $2.64.

Amount of Analyst Coverage

X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.73) per share.

Price to Book Value per Share Ratio

X4 Pharmaceuticals has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.74% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 6.04.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

X4 Pharmaceuticals does not currently pay a dividend.

Dividend Growth

X4 Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.48

News Sentiment

X4 Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $353,387.00 in company stock.

Percentage Held by Insiders

1.13% of the stock of X4 Pharmaceuticals is held by insiders.

Percentage Held by Institutions

72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Investor Day 2026: 10/29/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XFOR
• CIK: 1501697
• Web: www.x4pharma.com
• Phone: (857) 529-8300
• Fax: N/A
• Employees: 45
• Year Founded: 2010

Price Target and Rating

• Average Price Target for X4 Pharmaceuticals: $11.25
• High Price Target: $12.00
• Low Price Target: $10.00
• Potential Upside/Downside: +326.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.20 million
• Net Margins: -568.80%
• Pretax Margin: -568.98%
• Return on Equity: -63.05%
• Return on Assets: -36.89%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 11.30
• Quick Ratio: 11.02

Sales & Book Value

• Annual Sales: $35.11 million
• Price / Sales: 7.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.13 per share
• Price / Book: 1.24

Miscellaneous

• Outstanding Shares: 99,150,000
• Free Float: 98,027,000
• Market Cap: $261.76 million
• Optionable: No Data
• Beta: 0.46